Lv52
1390 积分 2023-06-29 加入
A way to resource is a big power to success.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2个月前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
2个月前
已完结
Unveiling Tirzepatide’s Therapeutic Spectrum: A Dual GIP/GLP‐1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health
2个月前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
3个月前
已完结
The genetics of human longevity: an intricacy of genes, environment, culture and microbiome
3个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
3个月前
已完结
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
4个月前
已完结
Glucagon-like peptide-1 Receptor Agonists and the Cardiorenal Axis in Type 2 Diabetes: A Focus On Dulaglutide
6个月前
已关闭
Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
6个月前
已完结
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
7个月前
已完结
皖公网安备34019202002308
